Source: FE Investegate

T3D Therapeutics: T3D Therapeutics Inc : First Patient Dosed in its Phase 2 Study

12:29 PM: First Patient Dosed in its Phase 2 Study

Read full article »
T3D Therapeutics's Competitors | T3D Therapeutics's News | T3D Therapeutics's Financials
Stay up-to-date with the latest news on T3D Therapeutics
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
John Didsbury's photo - Chairman & CEO of T3D Therapeutics

Chairman & CEO

John Didsbury

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on T3D Therapeutics